Anti-Müllerian hormone: a new marker for ovarian function

Jenny A Visser, Frank H de Jong, Joop S E Laven\(^1\) and Axel P N Themmen

Department of Internal Medicine and \(^1\)Division of Reproductive Medicine, Department of Obstetrics and Gynaecology, Erasmus MC, PO Box 1738, 3000 DR Rotterdam, The Netherlands

Correspondence should be addressed to J A Visser; Email: j.visser@erasmusmc.nl

Abstract

Anti-Müllerian hormone (AMH) is a member of the transforming growth factor β family of growth and differentiation factors. In the ovary, AMH has an inhibitory effect on primordial follicle recruitment as well as on the responsiveness of growing follicles to follicle-stimulating hormone (FSH). The ovary-specific expression pattern in granulosa cells of growing nonselected follicles makes AMH an ideal marker for the size of the ovarian follicle pool. This review summarizes recent findings concerning AMH and its role as a marker for the quantitative aspect of ovarian reserve as well as ovarian dysfunction.

Introduction

The ovarian reserve, constituted by the size of the ovarian follicle pool and the quality of the oocytes therein, declines with increasing age, resulting in the decrease of a woman’s reproductive function (te Velde et al. 1998). The size of the follicle pool is established at an early point in life. During fetal life, germ cells populate the ovary and become surrounded by somatic cells, forming the so-called primordial follicles. At birth, about 1 million oocytes are present. This number decreases during childhood, resulting in a primordial follicle pool of 300 000–500 000 follicles at menarche (Faddy et al. 1992). Throughout life, follicles leave the primordial follicle pool to enter the growing pool. The majority of these growing follicles will be lost as a result of atresia, unless they are rescued by follicle-stimulating hormone (FSH). This rescue by FSH starts after puberty when the pituitary-gonadal endocrine axis has been activated. Among the cohort of rescued follicles, only one follicle is selected to become the dominant follicle, which will ovulate under the influence of luteinizing hormone (LH) (McGee & Hsueh 2000). This process continues throughout life until the primordial follicle pool is exhausted and, as a consequence, growing follicles are no longer present in the ovary, resulting in menopause. This classical view of a finite primordial follicle pool has been challenged recently by Johnson et al. (2004, 2005), who showed that germline stem cells can repopulate a germ cell-depleted postnatal ovary and renew the primordial follicle pool. However, it remains unknown to what extent this process delays the onset of menopause.
In recent years, accumulated data indicate that anti-Müllerian hormone (AMH) may fulfill this role.

**Anti-Müllerian hormone (AMH)**

AMH, also known as Müllerian inhibiting substance (MIS), has been mainly studied for its regulatory role in male sex differentiation. AMH, produced by the Sertoli cells of the fetal testis, induces the regression of the Müllerian ducts, the anlagen of the female reproductive tract (Josso et al. 1993, Lee & Donahoe 1993). However, after birth, this sex-dimorphic expression pattern is lost and AMH is also expressed in granulosa cells of growing follicles in the ovary.

Detailed studies in rodents have shown that AMH expression starts in the columnar granulosa cells of primary follicles immediately after differentiation from the flattened pregranulosa cells of primordial follicles. Expression is highest in granulosa cells of preantral and small antral follicles, and gradually diminishes in the subsequent stages of follicle development. AMH is no longer expressed during the FSH-dependent final stages of follicle growth (Fig. 1). In addition, AMH expression disappears when follicles become atretic. The level of expression in follicles of the same class does not seem to change during the estrous cycle in rat, although some heterogeneity was observed in AMH expression in preantral and small antral follicles (review by Durlinger et al. 2002a).

Interestingly, two major regulatory steps of folliculogenesis, initial follicle recruitment and cyclic selection for dominance (McGee & Hsueh 2000), flank this window of expression. Analysis of the follicle dynamics in AMH null mice provided more insight into the intraovarian role of AMH and revealed that AMH specifically affects these two regulatory steps. Ovaries of 4-month-old AMH null mice contained almost threefold more small nonatretic growing follicles than their wild-type littermates, accompanied by a decrease in the number of primordial follicles (Durlinger et al. 1999). This increased recruitment had already started before the initiation of the estrous cycle, since a higher number of growing follicles was already evident in AMH null mice at day 25. These results indicate that, in the absence of AMH, primordial follicles are recruited at a faster rate. Consequently, the primordial follicle pool is prematurely exhausted and estrous cycling stops at an earlier age in AMH null mice (Durlinger et al. 1999). In *vitro* culture of neonatal ovaries in the presence of AMH confirmed the inhibitory effect of AMH on primordial follicle recruitment (Durlinger et al. 2002b). Based on the low FSH levels measured in AMH null mice in the presence of an increased number of growing follicles, it was hypothesized that, in the absence of AMH, follicles are more sensitive to FSH. Indeed, AMH inhibited FSH-dependent follicle growth of cultured mouse preantral follicles (Durlinger et al. 2001). Similarly, in granulosa cell cultures, AMH attenuates the FSH-dependent increase in aromatase activity and LH receptor expression (di Clemente et al. 1994). Furthermore, an *in vivo* study in which FSH levels were modulated showed that in the presence of both low and high serum FSH concentrations more growing follicles are found in AMH null mice than in wild-type mice (Durlinger et al. 2001). This inhibitory effect of AMH on FSH sensitivity of follicles could play a role in the process of selection. It is thought that each follicle exerts its own threshold FSH concentration that has to be exceeded to allow selection. A role for AMH in this process is indirectly supported by the differential expression level of AMH in nonatretic, large preantral and small antral follicles in the rat ovary (Baarends et al. 1995). A low expression of AMH within the follicle would diminish the threshold level for FSH, allowing these follicles to continue growth and to ovulate in the next estrous cycle.

Although they are mostly based on rodent studies, these results also appear to apply to the human ovary. In women, AMH expression can first be observed in granulosa cells of primary follicles, and expression is strongest in preantral and small antral follicles (≤4 mm). AMH expression disappears in follicles of increasing size and is almost lost in follicles larger than 8 mm, where only very weak staining remains, restricted to the granulosa cells of the cumulus (Weenen et al. 2004). This expression pattern suggests that, also in man, AMH may play a role in initial recruitment and in the selection of the dominant follicle.

**Figure 1** AMH expression in mouse ovaries. (A) AMH is expressed in granulosa cells of primary (P), preantral (PA) and small antral (SA) follicles. (B) AMH expression disappears in antral (A) and atretic (At) follicles. Expression is lost last in the granulosa cells surrounding the oocytes. AMH expression was detected using a monoclonal antibody that recognises rat, mouse and human AMH. Magnification × 200.
(Fig. 2). The possible mechanisms of action of AMH are reviewed elsewhere (Durlinger et al. 2002a, Visser 2003).

AMH as a marker for ovarian aging

The specific expression pattern of AMH in growing nonselected follicles has prompted us and others to investigate whether serum AMH levels are indicative for the size of the growing follicle pool. As discussed above, the quantitative aspect of ovarian aging is reflected by a decline in the size of the primordial follicle pool. Direct measurement of the primordial follicle pool is impossible. However, the number of primordial follicles is indirectly reflected by the number of growing follicles (Scheffer et al. 1999). Hence, a factor primarily secreted by growing follicles will reflect the size of the primordial follicle pool. Since AMH is expressed by growing follicles up to selection (Durlinger et al. 2002a), and can be detected in serum (Hudson et al. 1990, Lee et al. 1996), it is a promising candidate.

In young normal ovulatory women, early follicular phase hormone measurements at 3-year intervals revealed that serum AMH levels decline significantly whereas serum levels of FSH and inhibin B and the number of antral follicles do not change during this interval (de Vet et al. 2002). Stratification for age revealed that both serum AMH levels and numbers of antral follicles decline with age (Fig. 3A). Importantly, a strong correlation of serum AMH levels with AFC was observed (Fig. 3B). This positive correlation was later confirmed by Fanchin et al. (2003b), who showed a stronger correlation between serum AMH levels and follicle count than between AMH and serum levels of inhibin B, FSH, and E2 on cycle day 3.

The results of de Vet et al. (2002) also suggest that changes in serum AMH levels occur relatively early in the sequence of events associated with ovarian aging. Substantially elevated serum levels of FSH are not found until cycles have already become irregular (Burger et al. 1999). Therefore, a marker that already shows a considerable change when cyclicity is still normal would better identify women with declining fertility. Indeed, in studies by van Rooij et al. (2004, 2005), in which several markers of aging were measured in normal women at 4-year intervals, serum levels of AMH gave the highest accuracy (ROC_{AUC} 0.87) to predict occurrence of menopausal transition within 4 years. When serum inhibin B levels and age were included in a multivariate model, the ROC_{AUC} improved to 0.92. Furthermore, compared to other ovarian reserve markers, only serum AMH level showed a mean longitudinal decline over time. Taken together, these data strongly suggest that serum levels of AMH can be used as a marker of ovarian aging.

The usefulness of serum AMH levels as a measure of the ovarian reserve was recently shown in young women after treatment for childhood cancer. Chemotherapy and radiotherapy treatment have adverse effects on the ovary in particular, resulting in loss of primordial follicles. Indeed, in cancer survivors, the partial loss of the ovarian reserve is reflected by increased FSH levels and decreased ovarian volume. Unexpectedly, the number of small antral follicles is unchanged (Bath et al. 2003), a finding that may reflect the low accuracy and observer dependency of AFC measurements. Nevertheless, serum AMH levels were decreased in these patients, supporting the use of serum AMH levels as an early predictor of the ovarian reserve.

AMH as a marker of ovarian responsiveness

AMH’s role as a peripheral signal of the size of the growing follicle pool may have important clinical benefits. In women undergoing treatment for infertility, ovarian aging is characterized by decreased ovarian responsiveness to exogenous gonadotropin administration and poor pregnancy outcome. On the one hand, correct identification of poor responders by assessment of their ovarian reserve before entering an in vitro fertilization (IVF) program is important. On the other hand, assessment of the ovarian reserve may also benefit patients that would generally be excluded from IVF programs because of advanced age.

Several studies have shown that AMH is an excellent marker to determine ovarian responsiveness also in an IVF program. Hormone measurements in the early follicular phase (day 3 of spontaneous cycle), retrospectively or in a group of unselected patients, revealed that AMH levels are lower in patients with poor ovarian response than in women with normal response (Seifer et al. 2002, van Rooij et al. 2002), ovarian responsiveness being defined as the number of oocytes retrieved, or as cancellation due to impaired or absent follicular growth. In agreement with the studies described above, AMH serum levels were shown to be highly correlated with the number of antral follicles before treatment and number of oocytes retrieved upon ovarian stimulation (van Rooij et al. 2002). Logistic regression analysis for prediction of poor response showed that serum AMH levels had a better predictive value than serum levels of FSH, inhibin B and E2, and that the...
Figure 3 Serum AMH levels in normoovulatory women. (A) Box and whiskers plots show declining AMH levels with increasing age. AMH levels were measured at two time points with a 2.6 ± 1.7-year interval. (B) AMH levels positively correlate with numbers of antral follicles at visit 1 (closed circles, solid line) and visit 2 (open circles, dotted line). Reproduced from de Vet et al. (2002), with permission from American Society for Reproductive Medicine.

Table 1 Logistic regression for prediction of poor response after ovarian hyperstimulation.

<table>
<thead>
<tr>
<th>Univariate analysis</th>
<th>Odds ratio (95% CI)</th>
<th>P</th>
<th>ROC AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFC (per follicle)</td>
<td>0.70 (0.61–0.81)</td>
<td>&lt;0.001</td>
<td>0.86</td>
</tr>
<tr>
<td>AMH (per 0.1 µg/l)</td>
<td>0.82 (0.75–0.89)</td>
<td>&lt;0.001</td>
<td>0.85</td>
</tr>
<tr>
<td>FSH (per IU/l)</td>
<td>1.41 (1.22–1.63)</td>
<td>&lt;0.001</td>
<td>0.83</td>
</tr>
<tr>
<td>Inhibin B (per ng/l)</td>
<td>0.98 (0.97–0.99)</td>
<td>&lt;0.001</td>
<td>0.76</td>
</tr>
<tr>
<td>Age (per year)</td>
<td>1.07 (0.99–1.16)</td>
<td>NS</td>
<td>0.60</td>
</tr>
<tr>
<td>E2 (per pmol/l)</td>
<td>1.003 (1.000–1.006)</td>
<td>NS</td>
<td>0.52</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Multivariate analysis</th>
<th>OR (95% CI)</th>
<th>ROC AUC (final model)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All variables</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AFC (per follicle)</td>
<td>0.77 (0.65–0.90)</td>
<td>0.001</td>
</tr>
<tr>
<td>Inhibin B (per pg/ml)</td>
<td>0.98 (0.97–0.99)</td>
<td>0.006</td>
</tr>
<tr>
<td>FSH (per IU/l)</td>
<td>1.27 (1.07–1.50)</td>
<td>0.006</td>
</tr>
<tr>
<td>AFC excluded from analysis</td>
<td></td>
<td>0.92</td>
</tr>
<tr>
<td>AMH (per 0.1 µg/l)</td>
<td>0.90 (0.82–0.98)</td>
<td>0.018</td>
</tr>
<tr>
<td>Inhibin B (per pg/ml)</td>
<td>0.98 (0.97–0.99)</td>
<td>0.005</td>
</tr>
<tr>
<td>FSH (per IU/l)</td>
<td>1.26 (1.07–1.50)</td>
<td>0.006</td>
</tr>
</tbody>
</table>

predictive values for AMH and AFC were almost identical (ROCAUC 0.85 vs 0.86) (Table 1). Inclusion of FSH and inhibin B together with AMH in a multivariate model improved this predictive value to 0.90 (van Rooij et al. 2002) (Table 1). Similarly, cycle day-5 AMH levels are a better marker of ovarian responsiveness than inhibin B levels (Muttukrishna et al. 2004). Measurement of serum AMH levels has several advantages over other serum markers such as FSH, inhibin B and E2. To achieve a reliable predictive outcome, one single hormone measurement for AMH seems sufficient (Fanchin et al. 2005a). Furthermore, in contrast to FSH, inhibin B and E2, AMH levels remain relatively constant during the follicular phase and entire menstrual cycle (Cook et al. 2000, La Marca et al. 2004a, and our own unpublished results (F H J, J L, A T and Dr F Broekmans), consistent with the continuous, noncyclic growth of small follicles.

The absence of regulation of AMH by gonadotropins was shown in both rodents and man. Heterozygous AMH null mice present with an ovarian phenotype between that of wild-type and homozygous AMH null mice (Durlinger et al. 1999), suggesting that AMH acts as a paracrine rather than a systemic factor, and thus is not part of a negative feedback loop with involvement of gonadotropins. In agreement, treatment of IVF patients with a single, high dose of gonadotropin-releasing hormone (GnRH) agonist, resulting in a rise of endogenous FSH and LH, does not affect AMH serum levels (van Rooij et al. 2002). Similarly, in conditions where FSH levels are suppressed, such as pregnancy, AMH levels remain constant (La Marca et al. 2005). Thus, AMH is not influenced by the gonadotrophic status and reflects only the follicle population. The latter conclusion was confirmed in a more detailed study by Fanchin et al. (2003a), who treated women with FSH and human chorionic gonadotropin (hCG) after complete pituitary desensitization with a GnRH agonist. In a normal menstrual cycle, the early antral follicle pool remains intact throughout the follicular phase. However, upon ovarian hyperstimulation, all small antral follicles are stimulated to the preovulatory stage, thus providing a model to determine the relationship between AMH levels and follicle dynamics. Serum AMH levels, determined at three day during FSH treatment and at the day of hCG administration, decline significantly at each consecutive measurement (Fanchin et al. 2003a), reflecting the reduction in number of small antral follicles. A decline in serum AMH was also observed after FSH administration immediately following a spontaneous cycle (La Marca et al. 2004a). Moreover, on day 5 of gonadotropin therapy, levels of serum AMH and estradiol constitute an even better prediction of the ovarian response than cycle day 3 AMH levels (Penarrubia et al. 2005). However, from a clinical point of view, poor responders should be identified before treatment; therefore, it is more useful to determine serum AMH levels during a spontaneous cycle.

Throughout the controlled ovarian hyperstimulation protocol, serum AMH levels correlated well with the decrease in number of small antral follicles (≤12 mm) (Fanchin et al. 2003a), reflecting the complete conversion of small antral follicles into large antral follicles in response to FSH stimulation. Indeed, no correlation with the number of growing follicles (>12 mm) was observed (Fanchin et al. 2003a), in line with the low expression of AMH in these follicles (Weenen et al. 2004). In the days following hCG treatment, AMH serum levels initially declined, possibly as a result of the luteinization of granulosa cells upon hCG treatment that also causes a decline in E2 levels. During the midluteal phase, AMH serum levels slightly increased, probably as a result of the presence of newly developed, small antral follicles (Fanchin et al. 2005b). Thus, these changes in serum AMH levels seem to reflect follicle dynamics rather than regulation by gonadotropins.

All combined these studies strongly support a role of serum AMH level as a marker for ovarian responsiveness. However, the application of AMH to predict ongoing pregnancy seems limited, although day 3 serum AMH levels are higher in patients that become pregnant after IVF treatment than in those who do not (Hazout et al. 2004). However, data on pregnancy outcome were not stratified for the number of retrieved oocytes, which also in this study showed a positive correlation with AMH levels. Therefore, it is likely that the quantitative aspect of AMH as a marker of the ovarian reserve has contributed predominantly to the association with pregnancy outcome. Indeed, other studies did not observe a predictive value of AMH serum levels for ongoing pregnancy after IVF treatment (van Rooij et al. 2002, Penarrubia et al. 2005).

AMH as a marker for ovarian pathophysiology

The results of the studies described above indicate that serum AMH level can be used as a marker for the number of growing follicles. Besides being a marker for a diminishing follicle pool, serum AMH level can also serve as a marker in ovarian pathophysiology, such as polycystic ovary syndrome (PCOS), in which the antral follicle pool is enlarged. PCOS is one of the most common endocrine disorders in women of reproductive age (Franks 1995). It is characterized by anovulation manifested as oligo- or amenorrhea, elevated levels of circulating androgens, and polycystic ovaries as visualized by ultrasound. The diagnosis is based on the presence of at least two of the described characteristics, as defined by the Rotterdam Consensus (2004). PCOS encompasses a broad spectrum of clinical and biochemical characteristics, and, although the mechanisms leading to PCOS are still poorly understood, the common denominator is a disturbance in the selection of the dominant follicle resulting in anovulation. The defective selection mechanism results in an accumulation of small antral follicles, which contribute...
to the production of AMH. As discussed
above, studies in mice showed that AMH lowers the sen-
tivity of follicles to FSH (Durlinger et al. 2001), possibly
contributing to deranged follicle selection. It has been
suggested that aromatase activity in PCOS patients might
be decreased because follicles from PCOS women do not
produce large amounts of E₂ (Agarwal et al. 1996). AMH
also inhibits aromatase activity, as discussed above,
suggesting that AMH contributes to the severity of PCOS.

Initial studies showed that follicular fluid and serum of
PCOS women contained increased AMH levels (Fallat et al.
1997, Cook et al. 2002). In agreement with previous results
obtained in normal cycling women, also in PCOS women
serum AMH levels were correlated with antral follicle
number. The two- to threefold increase in the number of
growing follicles is reflected by a two- to threefold increase
in serum AMH level (Pigny et al. 2003, Laven et al. 2004)
(Fig. 4). In PCOS, the follicular excess is mainly caused by
an increase of small antral follicles up to 2–5 mm in size
(Hughesdon 1982, Jonard et al. 2003). Interestingly, in
follicles beyond this stage, AMH expression diminishes
(Weenen et al. 2004). Therefore, it is not surprising that
serum AMH levels positively correlate with the number of
2–5 mm, but not 6–9 mm, follicles in PCOS women (Pigny
et al. 2003). The finding that AMH levels are also increased
in the follicular fluid of PCOS women (Fallat et al. 1997)
suggests that the increase in serum AMH levels is not only
due to an increase in the number of growing follicles, but
may also result from increased AMH production per fol-
licle. So far little is known about the factors that regulate
AMH expression in the ovary.

Categorization of anovulatory women into groups with
or without polycystic ovaries (PCO), by number of antral
follicles (≥12 follicles per ovary measuring 2–9 mm) or
ovarian volume (>10 ml), revealed that serum AMH levels
were significantly higher in the PCO group than in non-
PCO patients (Laven et al. 2004). Nevertheless, serum
levels in non-PCO women were still significantly elevated
compared to those in control women (Fig. 4). This
suggests that the pool of smaller follicles, which is not
detected on ultrasound, may be increased and contributes
significantly to serum AMH levels in anovulatory women.
In a study by Eldar-Geva et al. (2005), categorization of
PCOS women by presence or absence of hyperandrogen-
ism showed that AMH levels were significantly different
between groups. Both groups had increased AMH levels
compared to control women, but levels in women with
PCO and hyperandrogenism were even further elevated.
Interestingly, the numbers of small antral follicles did not
differ between the two PCO groups, and multiple
regression analysis showed that follicle number and testos-
terone levels independently correlated with AMH serum
levels (Eldar-Geva et al. 2005). These results suggest that
the nonvisible pool of follicles may be further increased in
the presence of increased androgen levels. Indeed, in the
rhesus monkey, androgens stimulate the initiation of pri-
mordial follicle growth (Vendola et al. 1999). In addition,
androgens stimulate the proliferation of granulosa and
theca cells of growing follicles in rhesus monkeys
(Vendola et al. 1998). It is possible that under these con-
ditions follicles may produce more AMH. Since AMH
inhibits aromatase activity, local androgen concentrations
may be increased, possibly resulting in a positive feedback
mechanism between AMH and androgens. However, the
mechanism behind the positive association between
androgens and AMH in PCOS women requires further
studies, in particular, since in males during puberty an
inverse relationship between AMH and testosterone levels
was found (Rey et al. 1993). In this respect, it would be
interesting to analyze the expression level and pattern of
AMH by immunohistochemical analysis in polycystic
ovaries of women with or without hyperandrogenism.

In PCOS women, levels of serum AMH are also corre-
lated with other clinical features, such as cycle duration,
mean ovarian volume, testosterone and androstenedione
levels, and free androgen index, whereas no correlations
with inhibin B and E₂ levels were observed (Pigny et al.

A substantial proportion of PCOS women are obese and
exhibit insulin resistance and compensatory hyperinsuline-
emia (Dunaif 1997). The increased insulin levels in some
PCOS women can, in part, account for the hyperandro-
genism, because insulin acts synergistically with LH to
enhance androgen production by theca cells (Franks et al.
1999). However, serum AMH levels do not seem to corre-
late with BMI and insulin levels (Pigny et al. 2003, Laven
et al. 2004, Fleming et al. 2005). In contrast, in a small
study, La Marca et al. (2004b) observed a positive corre-
lation between serum AMH levels and the HOMA index,
an insulin resistance index calculated from fasting insulin
and fasting glucose levels.

---

**Figure 4** Serum AMH levels are increased in normogonadotropic anovulatory infertile women. Box and whisker plots show AMH levels in infertile women with PCO and those without (non-PCO) compared with control women. Reproduced from Laven et al. (2004) (©2004, Endocrine Society).
Improvement of insulin levels by insulin-lowering drugs, such as metformin and thiazolidinediones, which also indirectly affect androgen production, have been shown to be beneficial in PCOS women (Franks et al. 1999). In a study of obese PCOS women, metformin treatment suppressed androstenedione levels and ovulation rate (Fleming et al. 2005), although androgen levels were still above the upper limit of the normal range. Metformin administration also resulted in a small but significant reduction of serum AMH levels after 8 months of treatment, whereas the follicle number did not change significantly (Fleming et al. 2005). In a smaller study, metformin treatment for 6 months also decreased serum AMH levels only slightly (Piltonen et al. 2005), and levels remained strongly elevated compared to controls. Although AMH and androgen levels are positively correlated in PCOS women, the decrease in AMH levels may be secondary to the decrease in androgens upon metformin treatment. Furthermore, since the number of follicles is not likely to change in a short period of time, more detailed studies with longer follow-up are required to determine the long-term effect of insulin-lowering agents on AMH levels.

As in cycling women, AMH levels decline with increasing age in PCOS. However, the decrease in serum levels is significantly different from that in controls (Laven et al. 2004). A follow-up study investigated this phenomenon in more detail by measuring serum AMH levels in control and PCOS women on two occasions with a median time interval of 2.6 years. Although AMH levels had declined over time in both groups, the decline was less pronounced in PCOS women (Mulders et al. 2004). These results were confirmed by Piltonen et al. (2005), who showed that, in contrast to older control women with low to undetectable AMH levels, women with PCOS of the same age still had high AMH levels. This suggests that the ovarian aging process in PCOS women may have been slowed down, possibly due to suppressed primordial follicle outgrowth by the high levels of AMH observed in these women. However, it has also been suggested that exhaustion of the primordial follicle pool occurs later in PCOS women because their intrinsic primordial follicle pool may be increased (Webber et al. 2003). Data regarding the menopausal age in PCOS women are scarce. However, smaller studies seem to indicate that women with PCOS reach menopause at an older age (Dahlgren et al. 1992).

Conclusions and future directions

The studies described here indicate that serum AMH levels decrease with age in premenopausal women. In addition, serum levels of AMH correlate strongly with the number of antral follicles, suggesting that AMH levels by extension reflect the size of the primordial follicle pool. Assessment of the ovarian reserve is particularly important in the IVF clinic, where AMH may be useful as a predictor of poor response. Since a considerable proportion of subfertility is due to postponement of childbearing, measurement of AMH levels to assess the ovarian reserve may also be of interest in women in general. Assessment of the ovarian reserve, at least of the size of the ovarian follicle pool, may provide insight into the number of fertile years a woman has left. However, in order to determine whether serum AMH levels have prognostic value, additional prospective studies in a normal population are necessary to provide definite proof for this concept.

The positive correlation between serum AMH levels and number of antral follicles is also observed in women with PCOS. The elevated levels of AMH in these women strongly suggest that serum AMH levels may also be used in the diagnosis of PCOS. The difference in serum levels of AMH between subgroups of PCOS women suggests that AMH might also be used to establish a subclassification of this heterogeneous syndrome. However, more studies, preferably prospective, with thoroughly analyzed patient cohorts are necessary to define cutoff values. In addition, studies are necessary to determine whether serum AMH levels are also indicative of improved ovarian function upon treatment of PCOS women.

In conclusion, recent studies have validated the use of serum AMH levels as a marker for the quantitative aspect of ovarian reserve. Because AMH levels are strongly correlated with the size of the follicle pool, and because of the lack of cycle variations, serum levels of AMH are a good candidate for inclusion in standard diagnostic procedures to assess other ovarian dysfunctions, such as premature ovarian failure. Knowledge of the serum AMH levels in such conditions might provide more insight into the possible cause or effect of altered AMH levels. Genetic studies of well-defined population cohorts would also provide more knowledge about the role of AMH in ovarian physiology.

Acknowledgements

The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, Dennerstein L & Morse C 1995 The endocrinology of the menopausal transition: a cross-sectional study of a population-based...


Cook CL, Siow Y, Brenner AG & Fallat ME 2002 Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertility and Sterility 77 141–146.


Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 18 774–800.


Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM & Cohen-Bacrie P 2004 Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility and Sterility 82 1323–1329.


La Marca A, Orvieto R, Giuliani S, Jasonni VM, Volpe A & De Leo V 2004b Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertility and Sterility 82 970–972.


AMH as marker for ovarian function


Piktonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A & Tapanainen JS 2005 Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Human Reproduction 20 1820–1826.


Seifer DB, MacLaughlin DT, Christian BP, Feng B & Shelden RM 2002 Early follicular serum mullerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertility and Sterility 77 468–471.